Nepal vs Peru: Average cost of drugs for extensively drug-resistant tuberculosis
Nepal
2,853 constant 2022 US$
in 2024
Peru
3,884 constant 2022 US$
in 2024
Nepal rank
21st
Peru rank
18th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Nepal
- Peru
How they compare
Peru currently reports 3,884 constant 2022 US$ against 2,853 constant 2022 US$ in Nepal, a difference of 1,031 constant 2022 US$.
That makes Peru's figure about 1.4 times Nepal's.
Across all 7 years both countries report, Peru has been ahead every year.
Nepal ranks 21st and Peru ranks 18th of 56 countries.
Peru has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Nepal | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,811 constant 2022 US$ | 5,682 constant 2022 US$ | 2,871 constant 2022 US$ | Peru |
| 2020s | 2,995 constant 2022 US$ | 6,019 constant 2022 US$ | 3,025 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Nepal or Peru?
- Peru, at 3,884 constant 2022 US$ against 2,853 constant 2022 US$ in Nepal as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Nepal and Peru?
- 1,031 constant 2022 US$, with Peru ahead.
- How many years of comparable data are there for Nepal and Peru?
- 7 years are reported by both, from 2018 to 2024.
- How do Nepal and Peru rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Nepal ranks 21st and Peru ranks 18th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.